Halozyme Therapeutics (HALO) Stock Forecast, Price Target & Predictions
HALO Stock Forecast
Halozyme Therapeutics stock forecast is as follows: an average price target of $57.00 (represents a 24.86% upside from HALO’s last price of $45.65) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
HALO Price Target
The average price target for Halozyme Therapeutics (HALO) is $57.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $44.00. This represents a potential 24.86% upside from HALO's last price of $45.65.
HALO Analyst Ratings
According to 9 Wall Street analysts, Halozyme Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HALO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (66.67%), 3 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Halozyme Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Joseph Catanzaro | Piper Sandler | $52.00 | $46.72 | 11.31% | 13.91% |
| Jun 07, 2024 | Mitchell Kapoor | H.C. Wainwright | $65.00 | $51.44 | 26.36% | 42.39% |
| Jun 07, 2024 | Joseph Catanzaro | Piper Sandler | $51.00 | $51.44 | -0.86% | 11.72% |
| Jun 07, 2024 | Mohit Bansal | Wells Fargo | $58.00 | $51.44 | 12.75% | 27.05% |
| Jun 06, 2024 | Corinne Jenkins | Goldman Sachs | $44.00 | $51.44 | -14.46% | -3.61% |
| Jan 11, 2023 | - | Leerink Partners | $61.00 | $55.70 | 9.52% | 33.63% |
| Dec 21, 2022 | - | Morgan Stanley | $65.00 | $58.63 | 10.86% | 42.39% |
| Nov 28, 2022 | - | Wells Fargo | $65.00 | $55.53 | 17.04% | 42.39% |
| Nov 22, 2022 | - | J.P. Morgan | $54.00 | $52.74 | 2.39% | 18.29% |
The latest Halozyme Therapeutics stock forecast, released on Nov 15, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $52.00, which represents a 11.31% increase from the stock price at the time of the forecast ($46.72), and a 13.91% increase from HALO last price ($45.65).
Halozyme Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 5 |
| Avg Price Target | $52.00 | $52.00 | $54.00 |
| Last Closing Price | $45.65 | $45.65 | $45.65 |
| Upside/Downside | 13.91% | 13.91% | 18.29% |
In the current month, the average price target of Halozyme Therapeutics stock is $52.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 13.91% increase as opposed to Halozyme Therapeutics's last price of $45.65. This month's average price target is down 0.00% compared to last quarter, and down -3.70% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Nov 01, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Oct 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 07, 2024 | Wells Fargo | Market Outperform | Equal-Weight | Downgrade |
| Oct 04, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Oct 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 13, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 07, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 07, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Halozyme Therapeutics's last stock rating was published by Piper Sandler on Nov 04, 2024. The company gave HALO a "Neutral" rating, the same as its previous rate.
Halozyme Therapeutics Financial Forecast
Halozyme Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $216.03M | $221.04M | $162.14M | $181.50M | $208.98M | $152.37M | $117.28M | $102.00M | $115.83M | $136.46M | $89.02M | $121.70M | $65.32M | $55.22M | $25.35M | $53.66M | $46.23M | $39.15M | $56.95M | $30.87M | $29.57M |
| Avg Forecast | $307.25M | $295.30M | $279.97M | $257.67M | $293.61M | $252.17M | $204.94M | $199.74M | $231.00M | $216.08M | $199.95M | $179.26M | $192.05M | $191.17M | $138.63M | $128.25M | $101.54M | $105.84M | $104.12M | $84.88M | $120.01M | $59.90M | $66.68M | $42.96M | $56.93M | $54.96M | $42.76M | $67.83M | $35.78M | $28.46M |
| High Forecast | $322.29M | $309.76M | $293.68M | $262.99M | $314.18M | $255.82M | $204.94M | $199.74M | $237.20M | $235.13M | $209.74M | $188.04M | $201.46M | $191.17M | $138.63M | $128.25M | $101.54M | $105.84M | $104.12M | $84.88M | $120.01M | $59.90M | $66.68M | $42.96M | $56.93M | $54.96M | $42.76M | $67.83M | $42.93M | $34.15M |
| Low Forecast | $293.15M | $281.75M | $267.13M | $253.98M | $275.03M | $248.52M | $204.94M | $199.74M | $227.81M | $198.56M | $190.78M | $171.04M | $183.24M | $191.17M | $138.63M | $128.25M | $101.54M | $105.84M | $104.12M | $84.88M | $120.01M | $59.90M | $66.68M | $42.96M | $56.93M | $54.96M | $42.76M | $67.83M | $28.62M | $22.77M |
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 1.11% | 0.90% | 0.95% | 1.09% | 1.10% | 0.91% | 1.00% | 1.09% | 1.31% | 1.05% | 1.01% | 1.09% | 0.83% | 0.59% | 0.94% | 0.84% | 0.92% | 0.84% | 0.86% | 1.04% |
Halozyme Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $231.00M, with a low forecast of $227.81M, and a high forecast of $237.20M. HALO's average Quarter revenue forecast represents a 6.93% increase compared to the company's last Quarter revenue of $216.03M (Sep 23).
Halozyme Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $88.28M | $115.09M | $71.64M | $79.06M | $112.50M | $46.61M | $76.45M | $57.64M | $76.61M | $94.00M | $30.79M | $79.08M | $42.06M | $31.70M | $113.00K | $-29.69M | $-21.92M | $-10.96M | $6.01M | $-21.48M | $-26.64M |
| Avg Forecast | $116.16M | $111.64M | $105.85M | $97.42M | $111.00M | $95.34M | $77.48M | $96.90M | $87.34M | $81.69M | $75.60M | $88.10M | $61.86M | $68.69M | $49.81M | $80.09M | $36.48M | $38.03M | $37.41M | $38.97M | $43.12M | $21.52M | $23.96M | $124.30K | $20.46M | $19.75M | $15.37M | $6.01M | $-24.41M | $-25.57M |
| High Forecast | $121.85M | $117.11M | $111.03M | $99.43M | $118.78M | $96.72M | $77.48M | $116.29M | $89.68M | $88.89M | $79.30M | $105.71M | $74.23M | $68.69M | $49.81M | $96.10M | $36.48M | $38.03M | $37.41M | $46.76M | $43.12M | $21.52M | $23.96M | $149.16K | $20.46M | $19.75M | $15.37M | $7.22M | $-19.53M | $-20.46M |
| Low Forecast | $110.83M | $106.52M | $100.99M | $96.02M | $103.98M | $93.96M | $77.48M | $77.52M | $86.13M | $75.07M | $72.13M | $70.48M | $49.48M | $68.69M | $49.81M | $64.07M | $36.48M | $38.03M | $37.41M | $31.17M | $43.12M | $21.52M | $23.96M | $99.44K | $20.46M | $19.75M | $15.37M | $4.81M | $-29.29M | $-30.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.52% | 0.81% | 1.28% | 1.64% | 0.94% | 0.95% | 1.58% | 2.01% | 2.51% | 0.79% | 1.83% | 1.95% | 1.32% | 0.91% | -1.45% | -1.11% | -0.71% | 1.00% | 0.88% | 1.04% |
6 analysts predict HALO's average Quarter EBITDA for Dec 23 to be $87.34M, with a high of $89.68M and a low of $86.13M. This is -1.07% lower than Halozyme Therapeutics's previous annual EBITDA (Sep 23) of $88.28M.
Halozyme Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $81.84M | $74.75M | $39.62M | $57.70M | $61.63M | $22.68M | $60.11M | $66.77M | $216.59M | $91.46M | $27.89M | $73.16M | $36.21M | $25.82M | $-6.10M | $-34.40M | $-25.02M | $-14.62M | $1.80M | $-27.46M | $-32.90M |
| Avg Forecast | $167.00M | $153.12M | $146.40M | $133.39M | $152.55M | $124.67M | $96.14M | $75.70M | $107.36M | $91.90M | $81.98M | $68.82M | $71.66M | $46.74M | $60.73M | $62.56M | $49.71M | $54.72M | $56.20M | $35.30M | $68.32M | $25.16M | $31.82M | $-6.71M | $-23.54M | $-15.69M | $-18.24M | $1.80M | $-31.21M | $-31.58M |
| High Forecast | $177.63M | $162.87M | $155.72M | $135.93M | $173.06M | $127.66M | $96.15M | $90.84M | $111.29M | $98.19M | $87.20M | $82.58M | $85.99M | $46.74M | $60.73M | $75.07M | $49.71M | $54.72M | $56.20M | $42.37M | $68.32M | $25.16M | $31.82M | $-5.37M | $-23.54M | $-15.69M | $-18.24M | $2.16M | $-24.96M | $-25.26M |
| Low Forecast | $157.05M | $143.99M | $137.67M | $127.04M | $142.29M | $121.68M | $96.12M | $60.56M | $103.43M | $83.09M | $77.10M | $55.05M | $57.32M | $46.74M | $60.73M | $50.05M | $49.71M | $54.72M | $56.20M | $28.24M | $68.32M | $25.16M | $31.82M | $-8.06M | $-23.54M | $-15.69M | $-18.24M | $1.44M | $-37.45M | $-37.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | 0.91% | 0.58% | 0.81% | 1.32% | 0.37% | 0.96% | 1.34% | 3.96% | 1.63% | 0.79% | 1.07% | 1.44% | 0.81% | 0.91% | 1.46% | 1.59% | 0.80% | 1.00% | 0.88% | 1.04% |
Halozyme Therapeutics's average Quarter net income forecast for Dec 23 is $107.36M, with a range of $103.43M to $111.29M. HALO's average Quarter net income forecast represents a 31.19% increase compared to the company's last Quarter net income of $81.84M (Sep 23).
Halozyme Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $35.27M | $38.95M | $37.36M | $37.75M | $34.47M | $57.48M | $13.83M | $13.77M | $13.17M | $12.32M | $11.06M | $10.43M | $11.70M | $10.97M | $12.63M | $23.93M | $17.98M | $17.34M | $18.01M | $13.56M | $12.62M |
| Avg Forecast | $66.12M | $63.54M | $60.25M | $55.45M | $63.18M | $54.26M | $44.10M | $17.42M | $49.71M | $46.50M | $43.03M | $15.84M | $14.78M | $41.14M | $29.83M | $14.40M | $21.85M | $22.78M | $22.40M | $14.00M | $25.82M | $12.89M | $14.35M | $13.90M | $12.25M | $11.83M | $9.20M | $18.01M | $15.40M | $12.11M |
| High Forecast | $69.35M | $66.65M | $63.19M | $56.59M | $67.61M | $55.05M | $44.10M | $20.91M | $51.04M | $50.60M | $45.13M | $19.01M | $17.74M | $41.14M | $29.83M | $17.28M | $21.85M | $22.78M | $22.40M | $16.80M | $25.82M | $12.89M | $14.35M | $16.67M | $12.25M | $11.83M | $9.20M | $21.61M | $18.49M | $14.53M |
| Low Forecast | $63.08M | $60.63M | $57.48M | $54.65M | $59.18M | $53.48M | $44.10M | $13.94M | $49.02M | $42.73M | $41.05M | $12.67M | $11.83M | $41.14M | $29.83M | $11.52M | $21.85M | $22.78M | $22.40M | $11.20M | $25.82M | $12.89M | $14.35M | $11.12M | $12.25M | $11.83M | $9.20M | $14.40M | $12.32M | $9.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 0.91% | 2.36% | 2.55% | 0.84% | 1.93% | 0.96% | 0.63% | 0.58% | 0.55% | 0.79% | 0.40% | 0.91% | 0.76% | 0.91% | 1.95% | 1.52% | 1.88% | 1.00% | 0.88% | 1.04% |
Halozyme Therapeutics's average Quarter SG&A projection for Dec 23 is $49.71M, based on 6 Wall Street analysts, with a range of $49.02M to $51.04M. The forecast indicates a 40.94% rise compared to HALO last annual SG&A of $35.27M (Sep 23).
Halozyme Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 6 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $0.62 | $0.57 | $0.29 | $0.43 | $0.45 | $0.16 | $0.44 | $0.48 | $1.53 | $0.64 | $0.20 | $0.54 | $0.27 | $0.19 | $-0.04 | $-0.24 | $-0.17 | $-0.10 | $0.01 | $-0.19 | $-0.26 |
| Avg Forecast | $1.28 | $1.18 | $1.13 | $1.02 | $1.17 | $0.96 | $0.74 | $0.69 | $0.82 | $0.71 | $0.63 | $0.38 | $0.30 | $0.36 | $0.47 | $0.46 | $0.38 | $0.42 | $0.43 | $0.32 | $0.53 | $0.19 | $0.25 | $-0.02 | $-0.18 | $-0.12 | $-0.14 | $0.01 | $-0.25 | $-0.24 |
| High Forecast | $1.36 | $1.25 | $1.20 | $1.04 | $1.33 | $0.98 | $0.74 | $0.69 | $0.86 | $0.75 | $0.67 | $0.41 | $0.32 | $0.36 | $0.47 | $0.46 | $0.38 | $0.42 | $0.43 | $0.32 | $0.53 | $0.19 | $0.25 | $-0.02 | $-0.18 | $-0.12 | $-0.14 | $0.01 | $-0.20 | $-0.19 |
| Low Forecast | $1.21 | $1.11 | $1.06 | $0.98 | $1.09 | $0.94 | $0.74 | $0.69 | $0.79 | $0.64 | $0.59 | $0.36 | $0.28 | $0.36 | $0.47 | $0.46 | $0.38 | $0.42 | $0.43 | $0.32 | $0.53 | $0.19 | $0.25 | $-0.02 | $-0.18 | $-0.12 | $-0.14 | $0.01 | $-0.30 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 0.90% | 0.76% | 1.44% | 1.24% | 0.34% | 0.95% | 1.25% | 3.61% | 1.47% | 0.63% | 1.02% | 1.39% | 0.77% | 1.93% | 1.32% | 1.40% | 0.71% | 0.72% | 0.76% | 1.08% |
According to 6 Wall Street analysts, Halozyme Therapeutics's projected average Quarter EPS for Dec 23 is $0.82, with a low estimate of $0.79 and a high estimate of $0.86. This represents a 33.06% increase compared to HALO previous annual EPS of $0.62 (Sep 23).
Halozyme Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LRMR | Larimar Therapeutics | $6.69 | $20.33 | 203.89% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.75 | $106.93 | 138.95% | Buy |
| LEGN | Legend Biotech | $38.19 | $82.69 | 116.52% | Buy |
| VRDN | Viridian Therapeutics | $20.14 | $37.92 | 88.28% | Buy |
| CYTK | Cytokinetics | $50.22 | $83.23 | 65.73% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| ASND | Ascendis Pharma | $126.51 | $190.21 | 50.35% | Buy |
| EWTX | Edgewise Therapeutics | $31.44 | $45.00 | 43.13% | Buy |
| BGNE | BeiGene | $189.23 | $255.80 | 35.18% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| HALO | Halozyme Therapeutics | $45.65 | $57.00 | 24.86% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| PTGX | Protagonist Therapeutics | $41.11 | $50.00 | 21.62% | Buy |
| INSM | Insmed | $66.29 | $76.25 | 15.02% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| AGIO | Agios Pharmaceuticals | $53.78 | $48.00 | -10.75% | Buy |
| EXEL | Exelixis | $34.45 | $30.50 | -11.47% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |